EMS‑Chemie shares jumped 7% on Wednesday when UBS upgraded the Swiss specialty polymer maker to Buy from Neutral. The broker cited clearer earnings visibility and a more attractive risk‑reward profile after the stock’s recent dip. Investors welcomed the shift, pushing the SIX‑listed ticker higher in trading for the day overall.

UBS highlighted EMS‑Chemie’s margin resilience and disciplined cost base, which outperformed peers despite soft volumes in key end markets. A strong share of specialty polymers shields pricing, while recent cost‑inflation easing lifts profitability. The broker also noted that the stock’s slump has trimmed valuation multiples, making the price‑earnings ratio more appealing.

UBS also praised EMS‑Chemie’s solid balance sheet and steady free cash flow, which provide a cushion amid uncertain industrial demand. While the broker stopped short of forecasting a near‑term volume rebound, it expects the company’s conservative capital allocation and limited M&A activity to limit downside risk. Market participants will monitor end‑market trends for signs of recovery.